Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2005
11/17/2005WO2005107814A2 Process for the preparation of doxorubicin conjugates with lactosaminated human albumin and the obtained conjugates
11/17/2005WO2005107813A1 Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative
11/17/2005WO2005107812A1 Permeation enhancing compositions for anticholinergic agents
11/17/2005WO2005107811A2 Drug delivery device
11/17/2005WO2005107788A1 Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
11/17/2005WO2005107770A1 Use of equol for treating skin diseases
11/17/2005WO2005107759A1 Bh4-responsive hyperphenylalaninemia remedies
11/17/2005WO2005107733A1 Dermatological external preparation for local anesthesia
11/17/2005WO2005107728A2 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
11/17/2005WO2005107723A2 Transdermal delivery systems and transdermal chelation preparations
11/17/2005WO2005107719A2 Pharmaceutical composition comprising hydrophobic drug having improved solubility
11/17/2005WO2005107705A2 Extended therapeutic effect ocular implant treatments
11/17/2005WO2005107660A1 Condom with a coating and composition
11/17/2005WO2005107387A2 Targeting of radioimagining and radiotherapy agents
11/17/2005WO2005082337A3 Compositions comprising prodrugs of proton pump inhibitors
11/17/2005WO2005082048A3 Dissolvable film and method of manufacture
11/17/2005WO2005077423A3 Adept or gdept producing acetaldehyde
11/17/2005WO2005021044A3 Nanoparticles for delivery of nucleic acids and stable double-stranded rna
11/17/2005WO2005000222A3 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005WO2001065911A9 Improved poloxamer and poloxamine compositions for nucleic acid delivery
11/17/2005US20050256360 Methods of enhancing radiation effects with metal nanoparticles
11/17/2005US20050256211 Patient oxygenation using stabilized fluorocarbon emulsions
11/17/2005US20050256194 Denaturants for sympathomimetic amine salts
11/17/2005US20050256188 Formulations of anthraquinone derivatives
11/17/2005US20050256182 Formulations of anti-pain agents and methods of using the same
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256082 Allergen inactivator
11/17/2005US20050256060 Mono-and disaccharide derivatives
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050256045 Apparatus and method for transdermal delivery of parathyroid hormone agents
11/17/2005US20050256038 Stable pharmaceutical compsition containing factor VIII
11/17/2005US20050256030 Heterocyclic self-immolative linkers and conjugates
11/17/2005US20050255172 Hydrogen peroxide-based skin disinfectant
11/17/2005US20050255164 Solid nano pharmaceutical formulation and preparation method thereof
11/17/2005US20050255163 Co-grinding process for the preparation of a ternary composition
11/17/2005US20050255162 Hydrophobic biomolecular structure
11/17/2005US20050255161 Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255153 Mixture of deprotonatable lipid, such as polyoxyethylene glycol or polyamide lipid with buffered aqueous solution of charged drug
11/17/2005US20050255152 System for enhanced targeted delivery
11/17/2005US20050255149 Transdermal absorption preparation
11/17/2005US20050255143 Method of use of carboxylated polysaccharides topically on the eyeball
11/17/2005US20050255138 Active agent transport systems
11/17/2005US20050255131 Clindamycin compositions and delivery system therefor
11/17/2005US20050255130 Retinoid solutions and formulations made therefrom
11/17/2005US20050255124 HCV E1E2 vaccine compositions
11/17/2005US20050255120 Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
11/17/2005US20050255102 binds to alpha v beta 6 and not other alpha v integrins or non-specific integrins; inhibits the binding of alpha v beta 6 to latency associated peptide with an IC50 value lower than that of 10D5 and binds alpha v beta 6 in manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation
11/17/2005US20050255101 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
11/17/2005US20050255093 treating nervous system disorders induced by stroke or injury, injured by trauma to reduce oxidative stress, administering a conjugate of antioxidant enzyme and a clostridial neurotoxin cell binding domain, and a clostridial neurotoxin translocation domain; tissue-targeted therapy
11/17/2005US20050255091 Hydrogels for biomedical applications
11/17/2005US20050255083 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2005US20050255082 Polymeric coupling agents and pharmaceutically-active polymers made therefrom
11/17/2005US20050255079 Polymeric coupling agents and pharmaceutically-active polymers made therefrom
11/17/2005US20050255049 Formoterol and mometasone aerosol formulations
11/17/2005US20050255041 Administering monoclonal antibody or antigen binding fragment accession number 270404-01; primary and metastatic tumors
11/17/2005CA2821167A1 Drug delivery liposomes containing anionic polyols or anionic sugars
11/17/2005CA2580628A1 Berry oils and products
11/17/2005CA2566433A1 Therapeutic agent for bh4-responsive hyperphenylalaninemia
11/17/2005CA2566195A1 Process for the preparation of doxorubicin conjugates with lactosaminated human albumin and the obtained conjugates
11/17/2005CA2565658A1 Compounds for specific viral target
11/17/2005CA2565363A1 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
11/17/2005CA2565250A1 Cysteamines for treating complications of hypercholesterolemia and diabetes
11/17/2005CA2564634A1 Permeation enhancing compositions for anticholinergic agents
11/17/2005CA2563329A1 Medical device with coating for capturing genetically-altered cells and methods of using same
11/16/2005EP1595936A1 Antioxidative composition and composition for external use
11/16/2005EP1595891A1 Preparing albumin protein conjugated oligonucleotide probes
11/16/2005EP1595550A1 Selective retention of anti-cancer therapeutics in tumour cells through intra-cellular reaction with heat shock proteins
11/16/2005EP1595549A1 Dispersant for sustained release preparations
11/16/2005EP1595534A1 Gel composition comprising charged polymers
11/16/2005EP1595532A2 Sustained release of peptides from pharmaceutical compositions
11/16/2005EP1595142A2 Method for evaluating the efficacy of certain cancer treatments
11/16/2005EP1594979A2 Nanocylinder-modified surfaces
11/16/2005EP1594977A2 Reversible attachment of a membrane active polymer to a polynucleotide
11/16/2005EP1594548A1 Anthracycline-antibody conjugates
11/16/2005EP1594547A2 Chitosan-microparticles for ifn gene delivery
11/16/2005EP1594546A1 Salicylic acid derivative as efficacy enhancer and method
11/16/2005EP1594545A2 Pharmaceutical composition for transdermal or transmucosal administration
11/16/2005EP1594542A2 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
11/16/2005EP1594538A2 Composition to be administered to a living being and method for marking agents
11/16/2005EP1594535A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
11/16/2005EP1594534A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
11/16/2005EP1594533A2 Antibody vaccine conjugates and uses therefor
11/16/2005EP1594530A2 Albumin fusion proteins
11/16/2005EP1594523A2 Pharmaceutical botulinum toxin compositions
11/16/2005EP1594521A2 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
11/16/2005EP1594515A2 Drug formulation and delivery using crystalline methylated cyclodextrins
11/16/2005EP1594513A2 Carbohydrate conjugates to prevent abuse of controlled substances
11/16/2005EP1594488A2 Stabilized pharmaceutical compositions of safingol and methods of using the same
11/16/2005EP1594483A1 Uv stable transdermal therapeutic plaster
11/16/2005EP1594467A1 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
11/16/2005EP1594459A2 Drug delivery from rapid gelling polymer composition
11/16/2005EP1594436A2 Polymer conjugates of mutated neublastin
11/16/2005EP1594434A2 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
11/16/2005EP1594432A2 Short immunomodulatory oligonucleotides
11/16/2005EP1594366A2 Fat substitutes
11/16/2005EP1379138B1 Liquid formulations for dermal application in treatment of parasitic insects in animals
11/16/2005EP1368419B1 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
1 ... 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 ... 1712